Papel de la quimioterapia en el abordaje multidisciplinar del cáncer gástrico

Referencias bibliográficas

• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24 (14): 2137-50.
• Parkin DM, Pisani P, Ferlay J. Global Cancer Statistics. CA Cancer J Clin 1999; 49 (1): 33–64.
• Área de Epidemiologia Ambiental y Cancer. Centro Nacional de Epidemiologia Instituto de Salud Carlos III. La situación del cáncer en España. Ministerio de Sanidad y Consumo.
• Mari E, Floriani I, Tinazzi A et al. Efficacy of Adyuvant Chemotherpy after curative resection for gastric cancer: a Meta-Analysis of Published Randomised Trials. A Study of the GISCAD (Gruppo Italiano per lo studio dei Carcinomi Dell’Apparato Digerente). Ann Oncol 2000; 11(7): 837-843.
• Sakamoto J Paoletti X, on behalf of the Global Adv/adj Stomach Tumor Research through International Collaboration (GASTRIC). Meta-analyses of randomized trials assessing the interest of postoperative adyuvant chemotherapy in gastric cancer. Clin Oncol 2008;26: 18S.
• Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
• Macdonald JS, Smalley SR, Benedetti J et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: Update of the results of Intergroup Study INT-0116 (SWOG 9008). ASCO 2004 (abstr 6).
• Sakuramoto S, Sasako M, Yamaguchi T et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820.
• Cunningham D, Allum WH, Stenning SPet al. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
• Boige V, Pignon J, Saint-Aubert B et al. Final results of a randomized trial comparing preoperative 5-fluorouracil/cisplatin to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4510.
• Pyrhonen S, Kuitunen T, Nyandoto P et al. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non resecable gastric cancer. Br J Cancer 1995; 71 (3): 587-591.
• Glimelius B, Ekstrom K, Hoffman K et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8(2): 163-168.
• Murad A, Santiago F, Petroianu A et al. Modified therapy with 5-fluorouracil, doxorubicin an methotrexate in advanced gastric cancer. Cancer. 1993 Jul 1; 72 (1): 37-41.
• Schethauer W, Kornek G, Zeh B. Palliative chemotherapy vs. supportive care in patients with metastatic gastric cancer: a randomized trial. Second international conference on biology, prevention and treatment of gastrointestinal malignancies. Köln 1995;65-70.
• Wagner AD, Grothe W, Haerting J et al. Chemotherapy in advanced gastriccancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903–2909.
• Kim NK, Park YS, Heo DS et al. A phase III randomized study of 5FU and cisplatin versus 5FU, doxorubicin and mitomycin C versus 5FU alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813-3818.
• Webb A, Cunningham D, Scarffe JH et al. Randomizedd trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
• Van Cutsem E, Moiseyenko VM, Tjulandin S et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997.
• Dank M, Zaluski J, Barone C et al. Randomized phase III trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) versus CDDP + 5FU in 1rst line advanced gastric cancer patients. J Clin Oncol. 2005 ASCO Annual Meeting Proceeding (2005) 23: abstract 4003.
• Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
• Boku N, Yamamoto S, Shirao K et al. Randomized phase III study of 5-fluorouracil alone versus combination of irinotecan and cisplatin versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol 2007, 25(18S): 965s.
• Koizumi W, Narahara H, Hara T et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008 Mar;9(3): 215-21.
• Imamura H, Iishi H, Tsuburaya A et al. Irinotecan plus S-1 (IRIS) versus S-1 alone as first line treatment for advanced gastric cancer: Results of a randomized phase III study (GC030/TOP-002). Abstract 5, ASCO-GI 2008.